클라우딘 18.2 표적 치료 시장 보고서(2026년)

Claudin 18.2-targeted therapy represents a cutting-edge precision treatment for cancer, honed to zero in on the Claudin 18.2 protein that's unusually abundant on the surface of specific tumor cells. It precisely eliminates cancer cells, boosting treatment effectiveness while minimizing harm to normal tissues.

The primary therapy categories for claudin 18.2 targeted treatments include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and additional options. Monoclonal antibodies consist of laboratory-engineered molecules that bind to particular proteins on cancer cells, enabling the immune system to identify and eliminate them. These treatments are chiefly recommended for gastric cancer, pancreatic cancer, esophageal cancer, and various other types, delivered through intravenous, oral, or alternative methods. They are predominantly utilized by end-users such as hospitals, oncology centers, research institutes, and more.

Tariffs are impacting the claudin 18.2 targeted therapy market by increasing costs of imported biologic manufacturing equipment, specialized reagents, cell culture media, and advanced laboratory instruments used in antibody development and production. North America and Europe are most affected due to dependence on cross-border sourcing of bioprocessing inputs, while Asia-Pacific faces higher costs for clinical trial materials and biologics manufacturing components. These tariffs are raising development and production expenses and extending commercialization timelines. However, they are also encouraging localized biologics manufacturing, regional supply chain strengthening, and increased investment in domestic biopharmaceutical infrastructure.

The claudin 18.2 targeted therapy market research report is one of a series of new reports from The Business Research Company that provides claudin 18.2 targeted therapy market statistics, including claudin 18.2 targeted therapy industry global market size, regional shares, competitors with a claudin 18.2 targeted therapy market share, detailed claudin 18.2 targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the claudin 18.2 targeted therapy industry. This claudin 18.2 targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The claudin 18.2 targeted therapy market size has grown exponentially in recent years. It will grow from $1.6 billion in 2025 to $1.98 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to increasing prevalence of gastric and gastrointestinal cancers, advancements in antibody engineering technologies, expansion of oncology-focused clinical trials, rising investments in targeted cancer therapies, improved understanding of claudin protein biology.

The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted oncology drugs, rising demand for personalized cancer treatment, expansion of combination therapy approaches, growing oncology pipeline investments, increasing adoption of precision diagnostics. Major trends in the forecast period include increasing focus on biomarker-driven oncology therapies, rising development of claudin 18.2 monoclonal antibodies, growing expansion of indication-specific targeted treatments, enhanced integration of companion diagnostics, increasing strategic collaborations in precision oncology.

The increasing prevalence of gastrointestinal cancers is anticipated to boost the claudin 18.2 targeted therapy market in the future. Gastrointestinal (GI) cancers are malignant tumors that form in any section of the digestive system, ranging from the esophagus to the rectum. This surge in GI cancers stems mainly from poor diets high in processed foods and low in fiber, which foster gut inflammation and elevate cancer risk. Claudin 18.2 targeted therapy addresses these cancers by precisely homing in on the Claudin 18.2 protein, which is overexpressed on tumor cells, allowing drugs or antibodies to destroy cancer cells while preserving healthy tissue and enhancing overall treatment outcomes. For instance, in June 2025, the Centers for Disease Control and Prevention (CDC), a US-based public health organization, reported 147,931 new colorectal cancer cases in 2022 and 53,779 deaths from colorectal cancer in 2023. Thus, the growing incidence of gastrointestinal cancers is fueling expansion in the claudin 18.2 targeted therapy market.

Major companies in the claudin 18.2 targeted therapy market are prioritizing the creation of cutting-edge treatments, like monoclonal antibodies, to precisely target cancer cells expressing claudin 18.2 and improve patient results. A monoclonal antibody is a lab-produced protein engineered to attach specifically to one target, such as a protein on cancer cell surfaces, helping the immune system identify and eliminate those cells. For example, in March 2024, Astellas Pharma Inc., a pharmaceutical firm based in Japan, secured approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) to treat patients with CLDN18.2-positive cancer. This targeted treatment for advanced gastric and gastroesophageal junction cancer specifically attaches to the CLDN18.2 protein on tumor cells, triggering the immune system to eliminate them. Clinical studies demonstrated it substantially boosts progression-free and overall survival rates when used alongside chemotherapy, outperforming chemotherapy alone. This breakthrough therapy offers a fresh, potent choice for patients with HER2-negative, CLDN18.2-positive tumors, addressing a critical gap in managing aggressive gastric cancer.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to speed up its cell therapy strategy by broadening its pipeline with Gracell's cutting-edge CAR-T therapies for blood cancers and autoimmune diseases, utilizing Gracell's FasTCAR platform to enhance treatment effectiveness and production speed. Gracell Biotechnologies Inc. is a China-based clinical-stage biopharmaceutical company that develops claudin 18.2 targeted therapy.

Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the claudin 18.2 targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The claudin 18.2 targeted therapy market consists of sales of zolbetuximab, CMG901, and bispecific antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Claudin 18.2 Targeted Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses claudin 18.2 targeted therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for claudin 18.2 targeted therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The claudin 18.2 targeted therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates; Other Therapy Types
• 2) By Indication: Gastric Cancer; Pancreatic Cancer; Esophageal Cancer; Other Indications
• 3) By Route Of Administration: Intravenous; Oral; Other Route Of Administrations
• 4) By End-User: Hospitals; Oncology Centers; Research Institutes; Other End-Users
• Subsegments:
• 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies
• 2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies; Non-Igg-Like Bispecific Antibodies
• 3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates; Dna Damaging Agent-Based Antibody-Drug Conjugates; Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
• 4) By Other Therapy Types: Car-T Cell Therapy; Vaccines; Small Molecule Inhibitors
• Companies Mentioned: Bristol Myers Squibb Company; Amgen Inc.; Astellas Pharma Inc.; Jiangsu Hengrui Medicine Co. Ltd.; Shanghai Henlius Biotech Inc.; Legend Biotech Corporation; Zai Lab Limited; Harbour Biomed Ltd.; CARsgen Therapeutics Holdings Limited; Genor Biopharma Co. Ltd.; Phanes Therapeutics Inc.; Suzhou Zelgen Biopharmaceuticals Co. Ltd.; Triumvira Immunologics Inc.; SOTIO Biotech a.s.; Leap Therapeutics; Allogene Therapeutics; AskGene Pharma Inc.; Elpiscience Biopharmaceutical Co. Ltd.; I-Mab Biopharma Co. Ltd.; Antegene Biopharma Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Claudin 18.2 Targeted Therapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Claudin 18.2 Targeted Therapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Claudin 18.2 Targeted Therapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Claudin 18.2 Targeted Therapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics And Precision Medicine
  • 4.1.2 Artificial Intelligence And Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data And Cybersecurity
  • 4.1.4 Industry 4.0 And Intelligent Manufacturing
  • 4.1.5 Fintech, Blockchain, Regtech And Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Focus On Biomarker-Driven Oncology Therapies
  • 4.2.2 Rising Development Of Claudin 18.2 Monoclonal Antibodies
  • 4.2.3 Growing Expansion Of Indication-Specific Targeted Treatments
  • 4.2.4 Enhanced Integration Of Companion Diagnostics
  • 4.2.5 Increasing Strategic Collaborations In Precision Oncology

5. Claudin 18.2 Targeted Therapy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Centers
• 5.3 Research Institutes
• 5.4 Specialty Cancer Clinics
• 5.5 Academic Medical Centers

6. Claudin 18.2 Targeted Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Claudin 18.2 Targeted Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Claudin 18.2 Targeted Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Claudin 18.2 Targeted Therapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Claudin 18.2 Targeted Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Claudin 18.2 Targeted Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Claudin 18.2 Targeted Therapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Claudin 18.2 Targeted Therapy Market Segmentation

• 9.1. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
• 9.2. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
• 9.3. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Oral, Other Route Of Administrations
• 9.4. Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Oncology Centers, Research Institutes, Other End-Users
• 9.5. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
• 9.6. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
• 9.7. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Microtubule Inhibitor-Based Antibody-Drug Conjugates, DNA Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
• 9.8. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

10. Claudin 18.2 Targeted Therapy Market Regional And Country Analysis

• 10.1. Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Claudin 18.2 Targeted Therapy Market

• 11.1. Asia-Pacific Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Claudin 18.2 Targeted Therapy Market

• 12.1. China Claudin 18.2 Targeted Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Claudin 18.2 Targeted Therapy Market

• 13.1. India Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Claudin 18.2 Targeted Therapy Market

• 14.1. Japan Claudin 18.2 Targeted Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Claudin 18.2 Targeted Therapy Market

• 15.1. Australia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Claudin 18.2 Targeted Therapy Market

• 16.1. Indonesia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Claudin 18.2 Targeted Therapy Market

• 17.1. South Korea Claudin 18.2 Targeted Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Claudin 18.2 Targeted Therapy Market

• 18.1. Taiwan Claudin 18.2 Targeted Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Claudin 18.2 Targeted Therapy Market

• 19.1. South East Asia Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Claudin 18.2 Targeted Therapy Market

• 20.1. Western Europe Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Claudin 18.2 Targeted Therapy Market

• 21.1. UK Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Claudin 18.2 Targeted Therapy Market

• 22.1. Germany Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Claudin 18.2 Targeted Therapy Market

• 23.1. France Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Claudin 18.2 Targeted Therapy Market

• 24.1. Italy Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Claudin 18.2 Targeted Therapy Market

• 25.1. Spain Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Claudin 18.2 Targeted Therapy Market

• 26.1. Eastern Europe Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Claudin 18.2 Targeted Therapy Market

• 27.1. Russia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Claudin 18.2 Targeted Therapy Market

• 28.1. North America Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Claudin 18.2 Targeted Therapy Market

• 29.1. USA Claudin 18.2 Targeted Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Claudin 18.2 Targeted Therapy Market

• 30.1. Canada Claudin 18.2 Targeted Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Claudin 18.2 Targeted Therapy Market

• 31.1. South America Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Claudin 18.2 Targeted Therapy Market

• 32.1. Brazil Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Claudin 18.2 Targeted Therapy Market

• 33.1. Middle East Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Claudin 18.2 Targeted Therapy Market

• 34.1. Africa Claudin 18.2 Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Claudin 18.2 Targeted Therapy Market Regulatory and Investment Landscape

36. Claudin 18.2 Targeted Therapy Market Competitive Landscape And Company Profiles

• 36.1. Claudin 18.2 Targeted Therapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Claudin 18.2 Targeted Therapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Claudin 18.2 Targeted Therapy Market Company Profiles
  • 36.3.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Jiangsu Hengrui Medicine Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Shanghai Henlius Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Claudin 18.2 Targeted Therapy Market Other Major And Innovative Companies

• Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

38. Global Claudin 18.2 Targeted Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Claudin 18.2 Targeted Therapy Market

40. Claudin 18.2 Targeted Therapy Market High Potential Countries, Segments and Strategies

• 40.1 Claudin 18.2 Targeted Therapy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Claudin 18.2 Targeted Therapy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Claudin 18.2 Targeted Therapy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer